Pharmaceuticals

Global Healthcare Weekly

In our global healthcare weekly, we focus on identifiying key stock catalysts for biotech companies this week. Atara Biotherapeutics (NASDAQ: ATRA) with a market cap of around $41.8 million, focuses on developing T-cell immunotherapies for cancers and autoimmune diseases. The firm’s lead candidate, The FDA has set a PDUFA priority review date for January 15, 2025. Tabelecleucel has breakthrough therapy designation (BTD) for this rare indication, and approval could solidify Atara’s pre Axsome Therapeutics Inc. (NASDAQ: AXSM) is a late-stage biopharmaceutical company with a market cap of $3.88 billion, developing treatments for central nervous system disorders. The firm ha A key upcoming catalyst is the PDUFA decision for AXS-07, a combination of meloxicam and rizatriptan for the treatment of migraines, expected on January 31, 2025. AXS-07 has shown potential SpringWorks Therapeutics Inc. (NASDAQ: SWTX) with a market cap of about $1.93 billion, is focused on targeted oncology therapies. Its pipeline includes investigational treatments for rare d Mirdametinib is being developed for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, a rare genetic disorder. The FDA has granted priority review with a PDUFA d Mesoblast Limited (NASDAQ: MESO) is a regenerative medicine company focused on developing cellular therapies. With a market cap of approximately $1.05 billion, the firm is working to commer A key upcoming catalyst is the PDUFA date for RYONCIL, scheduled for January 7, 2025. The FDA accepted the resubmission of the BLA on July 23, 2024. This product, if approved, could address

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 29 May 2025. Alzamend Neuro (NASDAQ: ALZN) reported that the initial subject in the Phase II “Lithium-in-Brain” trial has received its dosage of AL001 for comparison against lithium carbonate. The study’s primary findings are antic Revelation Biosciences (NASDAQ: REVB) priced a US$4m public offering of 3.64m shares (or equivalents) and warrants for up to 14.56m shares at US$1.10 per share and warrant. Warrants are exercisable at US$1.10 upon stoc IMUNON (NASDAQ: IMNN) completed a US$3.25m private placement by selling 7,222,223 common shares and short-term warrants for an additional 14,444,446 shares at US$0.45 per share. The warrants could generate up to US$6.5 Applied DNA Sciences (NASDAQ: APDN) will implement a 1‑for‑15 reverse stock split effective 2 June 2025. Shares closed down 37% at US$0.33. Intensity Therapeutics (NASDAQ: INTS) will showcase a Trials‑in‑Progress poster on its Phase 3 INVINCIBLE‑3 study of intratumoral INT230‑6 in metastatic soft‑tissue sarcoma at ASCO 2025. Shares closed up 34% at US$0.39 ORIC Pharmaceuticals (NASDAQ: ORIC) reported Phase 1b data for ORIC-944 in mCRPC, with 59% PSA50 and 24% PSA90 confirmed response rates. They also secured approximately US$125m via a private placement at US$6.50 per sh Immunic (NASDAQ: IMUX) announced the pricing of a public offering including pre-funded warrants exercisable immediately, Series A warrants exercisable until 31 December 2025, and Series B warrants exercisable starting Intellia Therapeutics (NASDAQ: NTLA) shares are currently down during premarket hours after reporting a Grade 4 liver enzyme elevation in a patient in the late-stage MAGNITUDE trial for its Regeneron (NASDAQ: REGN)-par

V小姐

1 month ago